Teva Pharmaceuticals announced that it will re-introduce vincristine, a cancer drug used in adult cancers and of special importance to pediatric oncology, to the market.
According to a statement from Teva, there was no indication of a possible shortage when the company removed vincristine from the market earlier this year. However, given the lifesaving potential of the drug and since there is no reliable single supply anticipated in the near term, Teva will re-introduce vincristine and plans to manufacture it at the company’s plant in the United States (U.S.).
Vincristine will be available for patients in the U.S. as early in 2020 as possible, according to the statement.
Read the full announcement here.
Stay tuned to ASCO in Action for updates on this and other cancer policy developments.